Cagrilintide and Semaglutide Combination Explored for Type 2 Diabetes

Type 2 diabetes is a chronic metabolic condition characterized by high blood sugar, often leading to serious health complications like cardiovascular disease and kidney damage. Current treatments, including GLP-1 receptor agonists like Semaglutide, have significantly improved glycemic control and weight management for many patients. However, there remains a need for even more effective therapies that can achieve greater reductions in HbA1c and body weight, especially for individuals not reaching their treatment goals. This study specifically aimed to evaluate the efficacy and safety of co-administering Cagrilintide with Semaglutide to address this unmet need.

As this record describes the study design and completion status, the detailed efficacy and safety results from this Phase 2 trial are not yet publicly available. The study was designed to rigorously evaluate the impact of the combination therapy on key metabolic parameters. > The primary outcome measure was the change in HbA1c (a marker of average blood sugar over 2-3 months) from baseline to 32 weeks, aiming to quantify the improvement in glycemic control. Secondary endpoints included changes in body weight, fasting plasma glucose, and lipid profiles, alongside a comprehensive assessment of adverse events to determine the safety and tolerability of the combination. The 92 enrolled participants completed the 32-week treatment period, and data analysis is expected to reveal whether the co-administration of Cagrilintide and Semaglutide offers superior benefits compared to monotherapy or placebo.